22 results
Keyword sorafenib Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Nexavar
sorafenib, Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Date of authorisation: 19/07/2006,
, Revision: 27, Authorised
Nexavar, INN: sorafenib EMA/347706/2014 EMEA/H/C/000690 … for the public Nexavar sorafenib This is a summary of the … contains the active substance sorafenib. It is available as tablets … -
List item
Human medicine European public assessment report (EPAR): Inlyta (updated)
axitinib, Carcinoma, Renal Cell
Date of authorisation: 03/09/2012, Revision: 9, AuthorisedInlyta has been compared with sorafenib (another cancer medicine … Inlyta was more effective than sorafenib in treating advanced renal … months in the patients taking sorafenib. Effects were better for … -
List item
Human medicine European public assessment report (EPAR): Fotivda
tivozanib, Carcinoma, Renal Cell
Date of authorisation: 24/08/2017,
, Revision: 1, Authorised
another approved medicine sorafenib (9 months). What are the … another approved medicine sorafenib. The most common side effects … tyrosine kinase inhibitors (e.g. sorafenib, sunitinib, pazopanib) and … -
List item
Human medicine European public assessment report (EPAR): Lenvima
lenvatinib mesylate, Thyroid Neoplasms
Date of authorisation: 28/05/2015,, Revision: 6, Authorised
DECISION acronym for the Phase 3 sorafenib trial: “StuDy ofsorafEnib in loCally advanced or metastatIc … acronym for the Phase 3 sorafenib trial: Study of (E7080) LEnvatinib … 2010). To date, one TKI, sorafenib, has been approved in the … -
List item
Human medicine European public assessment report (EPAR): Stivarga
regorafenib, Colorectal Neoplasms
Date of authorisation: 26/08/2013, Revision: 14, Authorisedwith HCC should have tried sorafenib before starting treatment … worsened after treatment with sorafenib, Stivarga was compared with … with HCC should have tried sorafenib before starting treatment … -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015,, Revision: 22, Authorised
-
List item
Human medicine European public assessment report (EPAR): Kisplyx
lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016,, Revision: 7, Authorised
second-line agents include TKIs: sorafenib, sunitinib, axitinib, and … Authorized Indication Sorafenib Jul 2006 Treatment of patients … -
List item
Human medicine European public assessment report (EPAR): Votrient
pazopanib, Carcinoma, Renal Cell
Date of authorisation: 14/06/2010, Revision: 20, Authorised -
List item
Human medicine European public assessment report (EPAR): Cabometyx (updated)
cabozantinib s-malate, Carcinoma, Renal Cell
Date of authorisation: 09/09/2016,, Revision: 4, Authorised
with the cancer medicine sorafenib. Cabometyx contains the active … -
List item
Human medicine European public assessment report (EPAR): Afinitor
everolimus, Carcinoma, Renal Cell, Breast Neoplasms, Pancreatic Neoplasms
Date of authorisation: 02/08/2009, Revision: 22, AuthorisedVEGF-targeted medicines (sunitinib, sorafenib or both). Patients who took … -
List item
Human medicine European public assessment report (EPAR): Vargatef
nintedanib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 21/11/2014,, Revision: 9, Authorised
-
List item
Human medicine European public assessment report (EPAR): Sutent (updated)
sunitinib, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Neuroendocrine Tumors
Date of authorisation: 19/07/2006, Revision: 35, Authorisedkinase inhibitors such as sorafenib, there remains a large unmet … -
List item
Human medicine European public assessment report (EPAR): Torisel (updated)
Temsirolimus, Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
Date of authorisation: 19/11/2007,, Revision: 29, Authorised
-
List item
Human medicine European public assessment report (EPAR): Cometriq
cabozantinib, Thyroid Neoplasms
Date of authorisation: 21/03/2014,, , 
, Revision: 12, Authorised
-
List item
Human medicine European public assessment report (EPAR): Aplidin
Plitidepsin, Multiple Myeloma
Date of refusal: 17/07/2018,, Refused
-
List item
Human medicine European public assessment report (EPAR): Adempas (updated)
riociguat, Hypertension, Pulmonary
Date of authorisation: 27/03/2014,, , Revision: 9, Authorised
-
List item
Human medicine European public assessment report (EPAR): Tyverb (updated)
lapatinib, Breast Neoplasms
Date of authorisation: 10/06/2008, Revision: 29, Authorised -
List item
Human medicine European public assessment report (EPAR): Cyramza
Ramucirumab, Stomach Neoplasms
Date of authorisation: 19/12/2014,, Revision: 7, Authorised
-
List item
Human medicine European public assessment report (EPAR): Zelboraf
vemurafenib, Melanoma
Date of authorisation: 17/02/2012, Revision: 18, Authorised -
List item
Human medicine European public assessment report (EPAR): Avastin
bevacizumab, Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell
Date of authorisation: 12/01/2005, Revision: 50, Authorised -
List item
Human medicine European public assessment report (EPAR): Javlor
vinflunine, Carcinoma, Transitional Cell, Urologic Neoplasms
Date of authorisation: 21/09/2009, Revision: 8, Authorised -
List item
Human medicine European public assessment report (EPAR): Rydapt
Midostaurin, Leukemia, Myeloid, Acute, Mastocytosis
Date of authorisation: 18/09/2017,, , Revision: 2, Authorised